Trypanosomatid Diseases. Molecular Routes to Drug Discovery. Drug Discovery in Infectious Diseases

  • ID: 2330266
  • April 2013
  • 576 Pages
  • John Wiley and Sons Ltd
1 of 4

This is the first resource to provide researchers in academia and industry with an urgently needed update on drug intervention against trypanosomatides. As such, it
covers every aspect of the topic from basic research findings, via current treatments to translational approaches in drug development and includes both human and livestock diseases. The outstanding editor and contributor team reads like a Who?s Who of the field, thus guaranteeing the outstanding quality of this ready reference.

Note: Product cover images may vary from those shown
2 of 4

Foreword IX

Acknowledgment XV

Preface XVII

List of Contributors XIX

Part One Disease Burden, Current Treatments, Medical Needs, and Strategic Approaches 1

1 Visceral Leishmaniasis – Current Treatments and Needs 3
Poonam Salotra, Ruchi Singh, and Karin Seifert

2 Chemotherapy of Leishmaniasis: A Veterinary Perspective 17
María Jesus Corral-Caridad and Jose María Alunda

3 Pharmacological Metabolomics in Trypanosomes 37
Darren J. Creek, Isabel M. Vincent, and Michael P. Barrett

4 Drug Design and Screening by In Silico Approaches 57
Mattia Mori and Maurizio Botta

5 Computational Approaches and Collaborative Drug Discovery for Trypanosomal Diseases 81
Sean Ekins and Barry A. Bunin

Part Two Metabolic Peculiarities in the Trypanosomatid Family Guiding Drug Discovery 103

6 Interaction of Leishmania Parasites with Host Cells and its Functional Consequences 105
Uta Schurigt, Anita Masic, and Heidrun Moll

7 Function of Glycosomes in the Metabolism of Trypanosomatid Parasites and the Promise of Glycosomal Proteins as Drug Targets 121
Melisa Gualdron-Lopez, Paul A.M. Michels, Wilfredo Qui~nones, Ana J. Caceres, Luisana Avilan, and Juan-Luis Concepcion

8 Glyoxalase Enzymes in Trypanosomatids 153
Marta Sousa Silva, Antonio E.N. Ferreira, Ricardo Gomes, Ana M. Tomas,
Ana Ponces Freire, and Carlos Cordeiro

9 Trypanothione-Based Redox Metabolism of Trypanosomatids 167
Marcelo A. Comini and Leopold Flohe

10 Thiol Peroxidases of Trypanosomatids 201
Helena Castro and Ana M. Tomas

11 Peroxynitrite as a Cytotoxic Effector Against Trypanosoma cruzi: Oxidative Killing and Antioxidant Resistance Mechanisms 215
Madia Trujillo, María Noel Alvarez, Lucía Piacenza, Martín Hugo, Gonzalo Peluffo, and Rafael Radi

12 Selenoproteome of Kinetoplastids 237
Alexei V. Lobanov and Vadim N. Gladyshev

13 Replication Machinery of Kinetoplast DNA 243
Rachel Bezalel-Buch, Nurit Yaffe, and Joseph Shlomai

14 Life and Death of Trypanosoma brucei: New Perspectives for DrugDevelopment 261
Torsten Barth, Jasmin Stein, Stefan Mogk, Caroline Sch€onfeld, Bruno K. Kubata, and Michael Duszenko

Part Three Validation and Selection of Drug Targets in Kinetoplasts 279

15 Rational Selection of Anti-Microbial Drug Targets: Unique or Conserved? 281
Boris Rodenko and Harry P. de Koning

16 Drug Targets in Trypanosomal and Leishmanial Pentose Phosphate Pathway 297
Marcelo A. Comini, Cecilia Ortíz, and Juan Jose Cazzulo

17 GDP-Mannose: A Key Point for Target Identification and Drug Design in Kinetoplastids 315
Sebastien Pomel and Philippe M. Loiseau

18 Transporters in Anti-Parasitic Drug Development and Resistance 335
Vincent Delespaux and Harry P. de Koning

19 Peptidases in Autophagy are Therapeutic Targets for Leishmaniasis 351
Roderick A.M. Williams

20 Proteases of Trypanosoma brucei 365
Dietmar Steverding

Part Four Examples of Target-Based Approaches and Compounds Under Consideration 383

21 Screening Approaches Towards Trypanothione Reductase 385
Mathias Beig, Frank Oellien, R. Luise Krauth-Siegel, and Paul M. Selzer

22 Redox-Active Agents in Reactions Involving the Trypanothione/Trypanothione Reductase-based System to Fight Kinetoplastidal Parasites 405
Thibault Gendron, Don Antoine Lanfranchi, and Elisabeth Davioud-Charvet

23 Inhibition of Trypanothione Synthetase as a Therapeutic Concept 429
Oliver Koch, Timo J€ager, Leopold Flohe, and Paul M. Selzer

24 Targeting the Trypanosomatidic Enzymes Pteridine Reductase and Dihydrofolate Reductase 445
Stefania Ferrari, Valeria Losasso, Puneet Saxena, and Maria Paola Costi

25 Contribution to New Therapies for Chagas Disease 473
Patricia S. Doyle and Juan C. Engel

26 Ergosterol Biosynthesis for the Specific Treatment of Chagas Disease: From Basic Science to Clinical Trials 489
Julio A. Urbina

27 New Developments in the Treatment of Late-Stage Human African Trypanosomiasis 515
Cyrus J. Bacchi, Robert T. Jacobs, and Nigel Yarlett

Index 531

Note: Product cover images may vary from those shown
3 of 4

Volume Editors:. . Timo Jäger studied biology at the Technical University of Braunschweig, Germany, where he also received his PhD. He worked as a Postdoc at the German Research Centre for Biotechnology, Braunschweig, and served as Head of Biological Research and Development for MOLISA GmbH in Magdeburg, Germany. His research centered on the redox metabolism of pathogens, function and catalytic mechanism of peroxiredoxins, target evaluation, characterization, and drug development against infectious diseases, especially tuberculosis and trypanosomiasis. He is currently Managing Director of the Coordination Office of the German Centre for Infection Research DZIF in Braunschweig.. . Oliver Koch studied pharmacy and computer science at the Philipps-University of Marburg, Germany, where he also received his PhD in the field of computer-aided drug design. During his post-doctoral studies, he worked as a scientific software engineer at the Cambridge Crystallographic Data Centre (CCDC) in Cambridge, UK, before joining the drug discovery department at MSD Animal Health Innovation GmbH, Germany. Currently, he is junior research group leader at the faculty of chemistry, TU Dortmund, Germany. His research interests focus on the development and application of computational methods in drug discovery and molecular design.. . Leopold Flohé studied philosophy, medicine and biochemistry and obtained his MD and the venia legendi for Biochemistry from the University of Tübingen, Germany. He served as Scientific Director for Grünenthal GmbH in Aachen, the German Biotechnology Centre (HZI) in Braunschweig and Molisa GmbH in Magdeburg, Germany, while simultaneously teaching at the local universities. His contributions to science were acknowledged with Honorary Degrees from the Universities of Buenos Aires and Montevideo, the Claudius-Galenus-Preis, the Klaus Schwarz Commemorative Medal, the Science and Humanity Price (OCC) and the Trevor Frank Slater Award and Gold Medal (SFRRI).. . Paul M. Selzer studied biology, parasitology, and biochemistry at the University of Tübingen, Germany, where he also received his PhD in biochemistry. He spent three years at the Molecular Design Institute and the Parasitology and Tropical Disease Research Laboratory at the University of California, San Francisco. During his career he has worked as a researcher and scientific manager for several pharmaceutical companies, and is currently Director, Molecular Discovery Sciences at MSD Animal Health Innovation GmbH, Germany. He is also a visiting professor and teacher at the Biochemistry Institute of the University of Tübingen, and an honorary professor of the Department of Infection, Immunity, and Inflammation at the University of Glasgow, UK.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The book will be shipped to you. The cover has a hard back.


If you have a more general question about our products please try our



Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.